Inactief instrument

Andere talen Hansa Biopharma AB Nasdaq Stockholm

Aandelen

SE0002148817

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Correction, Hansa Biopharma, increase in number of shares and votes	06/05
Correction: Hansa Biopharma: increase in number of shares and votes	03/05
Hansa Biopharma: increase in number of shares and votes	03/05
Hansa Biopharma Q1 - Improved European launch support	19/04
Hansa Biopharma interim report January-March 2024	18/04
Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	18/04
Hansa Biopharma Approves SEK372 Million Directed Share Issue	12/04
Hansa Biopharma Announces Successful Execution of a Directed Share Issue of SEK 372 million (~USD 34.6 million)	12/04
Hansa Biopharma AB Provides Preliminary Unaudited Revenue Guidance for the First Quarter Ending March 31, 2024	02/04
Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance	02/04
Hansa Biopharma publishes 2023 Annual and Sustainability Reports	21/03
Hansa Biopharma Hires New CFO	22/02
Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer	22/02
Hansa Biopharma AB Announces CFO Changes	22/02
Hansa Biopharma - Improved sales prospects	05/02
Hansa Biopharma Year-end report January-December 2023	02/02
Hansa Biopharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02/02
Hansa Biopharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	02/02
Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference	06/01
Hansa Biopharma and Newbridge Pharmaceuticals Forms Partnership to Enable Supply of Novel Treatment Idefirix to Kidney Transplant Patients in the Middle East and North Africa	06/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Hansa Biopharma AB Nasdaq Stockholm

Aandelen

SE0002148817

Andere talen

Filters